AMENDMENTS TO THE CLAIMS

The claims as listed below will replace all prior listings and presentations of claims in the above-identified application.

Please amend Claim 2 and 17, cancel Claims 21-36, and add new Claims 37-41 as follows:

1. **(Canceled).**

2. **(Currently Amended)** An implant for treating an ocular disorder ~~glaucoma in an eye~~, said implant having a longitudinal implant axis and comprising:

an outflow portion through which said longitudinal implant axis passes, said outflow portion shaped and sized to be:

(a) introduced into Schlemm's canal of [[the]] an eye with said portion of said longitudinal implant axis at an angle to Schlemm's canal; and

(b) received at least partially within Schlemm's canal regardless of a rotational orientation of the outflow portion about said longitudinal implant axis during said introduction;

a plurality of longitudinally spaced openings in the outflow portion, the openings allowing fluid to communicate from a lumen within the outflow portion to a location outside the outflow portion;

an inflow portion configured to be positioned within [[the]] an anterior chamber of the eye so as to permit communication of fluid from the anterior chamber ~~of the eye~~ to the outflow portion; and

an anchoring member extending from the implant and being disposed distally of the longitudinally spaced openings;

wherein said longitudinal implant axis extends through [[the]] a trabecular meshwork of the eye and is generally orthogonal to Schlemm's canal during said fluid communication.

3. **(Canceled).**

4. **(Canceled).**

5. **(Canceled).**

6. **(Canceled).**

7. **(Canceled).**

8. **(Canceled).**

9. **(Canceled).**

10. **(Canceled).**

11. **(Canceled).**

12. **(Canceled).**

13. **(Previously presented)** The implant of Claim 2, wherein the outflow portion has a distal end with a transverse dimension that varies along the longitudinal implant axis.

14. **(Previously presented)** The implant of Claim 13, wherein the distal end of the outflow portion has a generally conical shape.

15. **(Previously presented)** The implant of Claim 13, wherein the distal end of the outflow portion has at least one sloped surface.

16. **(Previously presented)** The implant of Claim 2, wherein the anchoring member comprises a surface that is generally transverse to the longitudinal implant axis.

17. **(Currently amended)** The implant of Claim 13 [[2]], wherein the distal end and the outflow portion are integrally formed.

18. **(Previously presented)** The implant of Claim 2, further comprising an intermediate section between the inflow portion and the outflow portion.

19. **(Previously presented)** The implant of Claim 2, wherein at least a portion of the implant is configured to reside within the trabecular meshwork of the eye.

20. **(Previously presented)** The implant of Claim 2, wherein the outflow portion is shaped and sized to be introduced through Schlemm's canal of the eye.

21.-36. **(Canceled).**

37. **(New)** The implant of Claim 2, wherein the implant comprises a therapeutic drug.

38. **(New)** The implant of Claim 37, wherein the implant comprises a polymer.

39. **(New)** The implant of Claim 37, wherein the implant includes a first portion and a second portion that is appended from the first portion, and wherein the first portion includes the lumen and the second portion carries the therapeutic drug.

40. **(New)** The implant of Claim 37, wherein at least a portion of the implant is coated with the therapeutic drug.

41. **(New)** The implant of Claim 37, wherein the implant comprises a biocompatible material with the therapeutic drug coated thereon.